title: A multicenter, randomized, double-blind, placebo-controlled, two-year trial to study the effect of nitrendipine on chronic renal transplant function.
abstract: The ongoing multicenter, randomized, double-blind, placebo-controlled trial investigates the effect of nitrendipine on kidney function after renal transplantation. Renal transplant recipients (6th-12th postoperative week, serum creatinine < 3 mg/dl) were divided into a normotensive (diastolic blood pressure < 90 mmHg) and a hypertensive group (diastolic blood pressure > or = 90, < 115 mmHg). Normotensive patients are randomly treated for 104 weeks with nitrendipine 2 x 5 mg daily or placebo, hypertensive patients with 2 x 10 mg - 2 x 20 mg nitrendipine daily or placebo and in case of inefficacy with additional antihypertensive drugs. Primary end point of the study is the renal transplant function. The trial was started in June 1990. One hundred and eight patients were included into the normotensive and 138 patients into the hypertensive group. Renal allograft function, cyclosporine trough levels and the donor characteristics were not different between the normotensive and hypertensive groups at entry into the study. After 12 months there was no significant change of renal transplant function in both groups. Cyclosporine trough levels were also similar in the normotensive and hypertensive group after 12 months. As expected, blood pressure decreased significantly after 12 months from 150 +/- 17/95 +/- 11 mmHg to 141 +/- 16/90 +/- 9 mmHg in the hypertensive group (p < 0.01). In contrast, in the normotensive group blood pressure increased significantly from 128 +/- 12/80 +/- 6 mmHg to 135 +/- 15/86 +/- 8 mmHg (p < 0.001). No normotensive but 4 hypertensive patients developed graft failure during the first 12 months of the study.
authors.affiliation: Department of Medicine, University of Berlin (Charité), Germany.
authors.forename: M
authors.initials: M
authors.lastname: Barenbrock
authors.forename: U
authors.initials: U
authors.lastname: Colmorgen
authors.forename: E
authors.initials: E
authors.lastname: Firschka
authors.forename: J
authors.initials: J
authors.lastname: Gellert
authors.forename: J
authors.initials: J
authors.lastname: Lippert
authors.forename: K
authors.initials: K
authors.lastname: Schröder
authors.forename: C
authors.initials: C
authors.lastname: Spieker
authors.forename: G
authors.initials: G
authors.lastname: Voigt-Ladner
authors.forename: K
authors.initials: K
authors.lastname: Wagner
authors.forename: H H
authors.initials: HH
authors.lastname: Neumayer
mesh_terms: D000293:Adolescent; D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007674:Kidney Diseases / Q000503:physiopathology / Q000601:surgery; D016030:Kidney Transplantation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009568:Nitrendipine / Q000627:therapeutic use*; D014184:Transplantation, Homologous
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D009568:Nitrendipine